Dr. Bhaskar is skilled in the management of adult solid tumours, paediatric solid tumours, haemato-oncology cases & paediatric cancers.
He is skilled in stem cell transplant - autologous, allogenic, haplo and MUD stem cell transplant.
Dr. Bhaskar’s primary interest is in the management of breast and ovarian cancers, paediatric cancer & all types of blood cancers, vis-à-vis leukaemia, lymphoma & myeloma
His secondary interests include treating lung cancers, GI cancers, prostate cancers and kidney cancers.
He also has a keen interest in preventive oncology.
Dr. Bhaskar has served as a principal investigator for the following clinical trials:
RONALIC trial- a phase III randomised controlled trial going at Cancer Institute (WIA), Adyar, Chennai, related to Role of Neutropenic diet in Acute Leukemia patients During Induction Chemotherapy.
Phase III RCT related to the role of Docetaxel and trastuzumab in HER2 positive Metastatic Breast Cancer at HCG Cancer Centre, Vishakapatnam.
Phase III RCT related to the role of Liposomal doxorubicin in recurrent ovarian cancer and metastatic Breast cancer at HCG Cancer Centre, Vishakapatnam.
Phase III RCT related to the role of oral etoposide with cisplatin in advanced small cell lung cancer at HCG Cancer Centre, Vishakapatnam.
He has served as a sub-principal investigator for the following clinical trials:
Phase III RCT related to the role of Nab-paclitaxel in Metastatic Breast Cancer at HCG Cancer Centre, Vishakapatnam.
He was selected to participate at CREDO 2019 – a research, skill and protocol development workshop organised by Tata Memorial Hospital, Mumbai and presented a topic for protocol development - a phase 2 single-arm study on the efficacy of pre-emptive use of plerixafor in decreasing the morbidity of autologous stem cell transplant patients.
Dr. Bhaskar has presented posters at numerous conmferences, namely:
‘Retrospective data on acute promyelocytic leukaemia from tertiary care oncology centre from India’ at International Conference for Korean Society Hematology (ICKSH), Seoul, South Korea, in 2019.
‘Retrospective data on Rhabdomyosarcoma from tertiary care oncology centre from India’ at Society international of pediatric oncology (SIOP) Asia 2019 at Abu Dhabi, UAE.
‘Single Institutional treatment outcomes of Acute promyelocytic leukaemia from India’ at International Conference for Indian Society Hematology (HEMATOCON), Kochi, India, in October 2019.
‘Rhabdomyosarcoma in teenage and young adults’ at TYACON conference 2018 at Chennai, India.
He has secured prizes in numerous quiz competitions.
Outcomes in rhabdomyosarcoma: Experience from a tertiary cancer centre in India. Cancer Research, Statistics, and Treatment, 2(1), 4.
Paper published in university journal of Tamil Nadu MGR University on topic CRIZOTINIB in ALK/ROS1 Mutation positive advanced Non-Small Cell Lung Cancer – a single centre experience from south India.
Real-time ultrasound-guided fine-needle aspiration cytology of intra-abdominal and intrapelvic masses-synergistic approach of radiologist and cytopathologist for better cellular yield - co-author.
HCG - The Specialist in Cancer Care, India’s largest provider of cancer care, is at the forefront of the battle against cancer. Through its network of 24 comprehensive cancer centers, spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.